Biosergen AS Market Cap ($124.84K)
Market Cap & Net Worth: Biosergen AS (BIOSGN)
Biosergen AS market cap. Biosergen AS (ST:BIOSGN) has a market capitalization of $124.84K (Skr1.16 Million) as of November 4, 2026. Listed on the ST stock exchange, this Sweden-based company holds position #31464 globally and #739 in its home market, demonstrating a 0.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Biosergen AS's stock price Skr0.49 by its total outstanding shares 2348232 (2.35 Million). Also see Biosergen AS cash conversion from operations for how efficiently the company converts equity into cash flow.
Biosergen AS Market Cap History (2021–2026)
Biosergen AS market cap history from 2021 to 2026. Data shows change from $1.37 Million to $124.84K (-39.24% CAGR). Check today's stock price for Biosergen AS for real-time trading data and today's change.
Index Memberships
Biosergen AS is a constituent of 1 market index:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
First North Sweden PI
FNSESEKPI
|
$15.29 Billion | 0.00% | #256 of 281 |
Weight: Biosergen AS's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Biosergen AS Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Biosergen AS's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore Biosergen AS (BIOSGN) equity growth momentum to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
0.16x
Biosergen AS's market cap is 0.16 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2021 | $1.37 Million | $8.57 Million | -$34.56 Million | 0.16x | N/A |
Competitor Companies of BIOSGN by Market Capitalization
Companies near Biosergen AS in the global market cap rankings as of November 4, 2026. Also see Biosergen AS (BIOSGN) total assets for a full breakdown of the balance sheet.
Key companies related to Biosergen AS by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #180 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #368 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #414 globally with a market cap of $68.22 Billion USD ( AU$96.41 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #494 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #180 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $530.76 |
| #368 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $973.36 |
| #414 | CSL Ltd | AU:CSL | $68.22 Billion | AU$198.72 |
| #494 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $228.44 |
Market Capitalization of Biosergen AS (2021–2026)
Market capitalization of Biosergen AS from 2021 to today. Between 2021 and today, Biosergen AS's market cap moved from $1.37 Million to $ 124.84K, with a yearly change of -39.24%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | Skr124.84K | -98.75% |
| 2025 | Skr9.99 Million | +7356.60% |
| 2024 | Skr133.93K | -39.77% |
| 2023 | Skr222.38K | -16.19% |
| 2022 | Skr265.34K | -80.63% |
| 2021 | Skr1.37 Million | -- |
End of Day Market Cap According to Different Sources
On Nov 4th, 2026 the market cap of Biosergen AS was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $124.84K USD |
| MoneyControl | $124.84K USD |
| MarketWatch | $124.84K USD |
| marketcap.company | $124.84K USD |
| Reuters | $124.84K USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Biosergen AS
Biosergen AB (publ), a biotech company, develops antifungal products. Its lead product is BSG005, an antifungal drug candidate for the treatment of invasive fungal infections in immunocompromised patients, including AIDS, cancer, and transplant recipients. The company was founded in 2004 and is based in Solna, Sweden.